RxDoctor Payments Data

Muhammad Salick, MD

Pulmonary Disease · Ashland, KYNPI 1952823254

Payments from drug & device makers

$5,019in general payments, 2019–2025

Across 141 payments — averaging $35.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Intuitive Surgical$1K
  • Sanofi$381
  • Grifols USA, LLC$323
  • Boehringer Ingelheim$316
  • Regeneron Healthcare Solutions, Inc.$157
  • plus $819 from 13 others

What the payments were for

  • Travel & lodging$1,09422%
  • Food & beverage$3,82576%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,019 in reported general payments places this provider in the 45th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$80,279
Medicare patients
290
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter200$168,361
Spiriva RespimatTiotropium Bromide50$31,217
Breo ElliptaFluticasone/Vilanterol21$12,339
Spiriva HandihalerTiotropium Bromide18$10,829
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,173
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,765
Advair HfaFluticasone Propion/Salmeterol11$3,321
Albuterol Sulfate HfaAlbuterol Sulfate59$2,459
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,023
Ventolin HfaAlbuterol Sulfate15$1,083
Wixela InhubFluticasone Propion/Salmeterol13$740
Azelastine Hcl29$526
Montelukast Sodium37$343
Fluticasone Propionate40$309
Pantoprazole Sodium28$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,794$180,700221 claims
Boehringer IngelheimSpiriva Respimat$316$31,21750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →